Biggest News Aggregation in the World
📰 Cigna News

Page 502 - Cigna News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Cigna. Real-time updates on events, politics, business and more.

FDA Grants Historic Approval for Alzheimer's Disease Therapy in Permissive Decision | Wilson Sonsini Goodrich & Rosati

On June 7, 2021, the U.S. Food and Drug Administration (FDA) approved Biogen, Inc.'s Aduhelm (aducanumab) to treat Alzheimer's disease through the FDA Accelerated Approval Program in a...
United States Wilson Sonsini Goodrich Rosati Centers For Medicare Medicaid Services National Institute Of Health Central Nervous System Drugs Advisory Committee Drug Administration

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Billionaire Burkle's SPAC Buys European Sporting Goods Retailers

Grocery store billionaire and Pittsburgh Penguins co-owner Ronald Burkle is getting into the sporting goods business. Burkle’s Yucaipa Acquisition, a SPAC that holds $345 million from an August IPO, has inked a deal to merge with Signa Sports United, a German-based online sporting goods retailer, according to a release from Signa. The deal, which values […]
Ronald Burkle Sporting Goods Ucaipa Spac Market Share Yucaipa Acquisition ரொனால்ட் பர்கில்
Source: yahoo.com

New Alzheimer's drug Aducanumab - cost, side effects, timeline and other questions answered

New Alzheimer’s drug Aducanumab – cost, side effects, timeline and other questions answered Patients and their families are starting to inquire about the new Alzheimer’s drug approved this week by the US Food and Drug Administration. Shipments of the medication are expected to go out in just a couple of weeks. Hospitals are on tap to administer treatment when needed. And there is serious division in the FDA, especially around the drug’s effectiveness. Aducanumab, to be sold under the br...
University Of Southern California United States Lon Schneider Chirfi Guindo Julia Biernot Memorial Healthcare Institute For Neuroscience
Source: ktvz.com

New Alzheimer's drug aducanumab: cost, side effects, timeline and other questions answered

New Alzheimer’s drug aducanumab: cost, side effects, timeline and other questions answered Patients and their families are starting to inquire about the new Alzheimer’s drug approved this week by the US Food and Drug Administration. Shipments of the medication are expected to go out in just a couple of weeks. Hospitals are on tap to administer treatment when needed. And there is serious division in the FDA, especially around the drug’s effectiveness. Aducanumab, to be sold under the brand...
University Of Southern California United States Lon Schneider Chirfi Guindo Julia Biernot Memorial Healthcare Institute For Neuroscience
Source: kvia.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science